logo
logo
ARAY stock ticker logo

Accuray Incorporated

NASDAQ•ARAY
CEO: Ms. Suzanne Winter M.B.A.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2007-02-08
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Contact Information
1240 Deming Way, Madison, WI, 53717-1954, United States
608-824-2800
www.accuray.com
Market Cap
$48.91M
P/E (TTM)
-1.4
26.4
Dividend Yield
--
52W High
$2.10
52W Low
$0.33
52W Range
5%
Rank68Top 98.2%
1.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q2 2026 Data

Revenue

$102.24M+0.00%
4-Quarter Trend

EPS

-$0.11+0.00%
4-Quarter Trend

FCF

-$17.09M+0.00%
4-Quarter Trend

2026 Q2 Earnings Highlights

Key Highlights

Six Month Revenue Decreased Total net revenue $196.2M, down 10% for six months ended December 31, 2025, driven by lower product volume.
Gross Profit Margin Compressed Gross profit $51.1M, down 33%; gross margin compressed to 26.0% due to sales mix shifts.
China Revenue Significantly Dropped China net revenue fell 53% to $32.9M for six months, severely impacting overall top-line performance.
Restructuring Charges Incurred Restructuring charges totaled $8.9M for six months, tied to FY26 Plan eliminating 15% of global workforce.

Risk Factors

Macroeconomic Pressures Persist Inflation, supply chain issues, and logistics costs expected to adversely affect gross margins through fiscal year 2026.
Financing Agreement Covenants Risk Compliance with leverage and coverage ratios under Amended Financing Agreement depends on future operating results.
Common Stock Delisting Threat Stock price volatility risks Nasdaq delisting due to Minimum Bid Requirement failure; liquidity and capital access threatened.
Technology Adoption Uncertainty Success requires physician acceptance of platforms against intense competition; failure limits market penetration and revenue growth.

Outlook

Liquidity Sufficient Next Twelve Months Current cash resources expected to fund operations and capital needs for at least the next 12 months.
FY26 Restructuring Completion Target FY26 Restructuring Plan, including workforce reduction, expected to be substantially completed by June 30, 2026.
2026 Notes Repayment Strategy Plan to use operating cash and Delayed Draw Facility proceeds to repay remaining $18.0M principal of 2026 Notes.
Remaining Performance Obligations Conversion Expect recognition of majority $14.1M in remaining performance obligations, primarily warranty revenue, over next 12 months.

Peer Comparison

Revenue (TTM)

ARAY stock ticker logoARAY
$436.97M
-3.6%
ANIK stock ticker logoANIK
$112.82M
+3.8%
OWLT stock ticker logoOWLT
$105.66M
+35.3%

Gross Margin (Latest Quarter)

MXCT stock ticker logoMXCT
92.4%
+16.1pp
SGHT stock ticker logoSGHT
87.3%
+2.5pp
TLSI stock ticker logoTLSI
86.7%
-2.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ANIK$203.48M-18.5-7.4%12.7%
SGHT$199.28M-5.1-55.7%35.4%
PROF$165.52M-3.7-85.7%3.3%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-3.3%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention

Deep Research

Next earnings:Apr 28, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data